A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
2008
British Journal of Psychiatry
Despite the prevalence and clinical significance of borderline personality disorder, its treatment remains understudied. Aims To evaluate treatment with variably dosed olanzapine in individuals with borderline personality disorder. Method In this 12-week randomised, double-blind trial, individuals received olanzapine (2.5–20 mg/day; n=155) or placebo (n=159) (trial registry: NCT00091650). The primary efficacy measure was baseline to end-point change on the Zanarini Rating Scale for Borderline
doi:10.1192/bjp.bp.107.037903
pmid:19043153
fatcat:okvogetusbcmbf43dtucrgxa64